Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaPevOX-1: Phase I pevonedistat plus CapeOX in platinum-refractory gastric cancer
jRCT2031190020Phase 1Active, not recruiting
- Sponsor
- Takeda
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pevonedistat in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Takeda. Primary endpoints: Safety and tolerability / Recommended dose determination and Pharmacokinetics of pevonedistat. Started Aug 2019; status: active, not recruiting.
02
Drugs
pevonedistat
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031190020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190020.